These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32165164)

  • 1. Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials.
    Giugliano D; Longo M; Maiorino MI; Bellastella G; Chiodini P; Solerte SB; Esposito K
    Diabetes Res Clin Pract; 2020 Apr; 162():108114. PubMed ID: 32165164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Garofalo C; Chiodini P; Ceriello A; Esposito K
    Cardiovasc Diabetol; 2020 Mar; 19(1):35. PubMed ID: 32192503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.
    Zhao LM; Huang JN; Qiu M; Ding LL; Zhan ZL; Ning J
    Medicine (Baltimore); 2021 Oct; 100(39):e27362. PubMed ID: 34596148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
    Giugliano D; Longo M; Scappaticcio L; Bellastella G; Maiorino MI; Esposito K
    Cardiovasc Diabetol; 2021 Dec; 20(1):236. PubMed ID: 34915880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
    Chang R; Liu SY; Zhao LM
    Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
    Karagiannis T; Tsapas A; Athanasiadou E; Avgerinos I; Liakos A; Matthews DR; Bekiari E
    Diabetes Res Clin Pract; 2021 Apr; 174():108737. PubMed ID: 33705820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study.
    Anyanwagu U; Mamza J; Donnelly R; Idris I
    Cardiovasc Diabetol; 2017 Aug; 16(1):107. PubMed ID: 28830436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
    Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
    Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
    Grenet G; Ribault S; Nguyen GB; Glais F; Metge A; Linet T; Kassai-Koupai B; Cornu C; Bejan-Angoulvant T; Erpeldinger S; Boussageon R; Gouraud A; Bonnet F; Cucherat M; Moulin P; Gueyffier F
    PLoS One; 2019; 14(6):e0217701. PubMed ID: 31237921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.